Ganesh Kaundinya - Momenta Pharmaceuticals Insider

Momenta Pharmaceuticals Inc -- USA Stock  

USD 18.40  0.65  3.66%

Co-Founder, Chief Scientific Officer and Sr. VP of Research

Dr. Ganesh Venkataraman Kaundinya, Ph.D., is Chief Operating Officer, Chief Scientific Officer of the Company. He is a cofounder of the Company and was the Company Chief Scientific Officer since September 2007. From September 2007 until his appointment as the Chief Operating Officer, Dr. Kaundinya was also a Senior Vice President of the Company. From April 2005 to September 2007, Dr. Kaundinya was the Company Senior Vice President, Research, and from January 2002 until April 2005, Dr. Kaundinya served as the Company Vice President, Technology
Age: 50  Founder Since 2017      
Kaundinya received his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Ganesh Kaundinya Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (12.35) % which means that it has lost $12.35 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (23.62) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. Momenta Pharmaceuticals operates under Drugs - Generic classification in USA and traded on NASDAQ. It employs 279 people.Momenta Pharmaceuticals Inc (MNTA) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 279 people. Momenta Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Momenta Pharmaceuticals Inc to your portfolio

Top Management

Momenta Pharmaceuticals Leadership Team
Bennett Shapiro, Director
James Anderson, President
Craig Wheeler, CEO, MBA
Georges Gemayel, Director, Ph.D
Matthew Ottmer, COO
Elizabeth Stoner, Director
John Bishop, President, MBA
JoseCarlos GutierrezRamos, Director, Ph.D
Bruce Leicher, President
James Sulat, Chairman, MBA
Corey Fishman, Director
Jim Anderson, President
James Roach, President, Ph.D
Young Kwon, President, Ph.D
Bruce Downey, Director
JoAnn Beltramello, President
Steven Gilman, Director
Anthony Manning, President, Ph.D
Marsha Fanucci, Director, MBA
Ganesh Kaundinya, Founder
Ian Fier, President, MBA
Richard Shea, CFO, CPA
Michael Franken, President
Thomas Koestler, Director, Ph.D
Scott Storer, President, MBA

Stock Performance

Momenta Pharmaceuticals Performance Indicators